JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-08-05 pm EDT
171.11 USD   -0.40%
08/05The Janssen Pharmaceutical Companies - European Commission Approves IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
AQ
08/05FOCUS : 5 Stocks for Yield Lovers
MS
08/04South Africa Health Regulator Flags First Death Linked to Johnson & Johnson COVID-19 Jab
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

06/27/2022 | 10:24am EDT

BEERSE, BELGIUM - The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a new treatment option with IMBRUVICA (ibrutinib) in an oral fixed-duration combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL).

Outcomes for patients with CLL have improved in the last decade with the advent of oral therapies that target the underlying disease biology.[1] This provides the opportunity to combine these novel treatments for an effective and convenient approach that results in deep responses with time-limited therapy.[1] If approved, I+V will be the first all-oral, once daily, fixed-duration combination treatment with a Bruton's tyrosine kinase (BTK) inhibitor for first-line treatment of patients with CLL.

'With this innovative treatment regimen, healthcare professionals would have the flexibility to use ibrutinib either in a fixed-duration combination or as a continuous therapy, helping them to better tailor frontline CLL therapy based on patients' individual needs,' said Edmond Chan, MBChB, M.D. (Res), EMEA Therapeutic Area Lead Haematology, Janssen-Cilag Limited. 'This recommendation brings us one step closer to European Commission (EC) approval and to providing patients with an all-oral, once daily, fixed-duration regimen, which until this point has not been available with the BTK inhibitor class of treatments.'

The CHMP positive opinion is supported by data from the pivotal Phase 3 GLOW study (NCT03462719), which demonstrated that I+V was superior to chlorambucil-obinutuzumab with respect to the primary endpoint, progression-free survival (PFS), in elderly or unfit patients with CLL (PFS hazard ratio [HR]: 0.216; 95 percent confidence interval [CI], 0.131 to 0.357; P

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
08/05The Janssen Pharmaceutical Companies - European Commission Approves IMBRUVICA (ibrutini..
AQ
08/05FOCUS : 5 Stocks for Yield Lovers
MS
08/04South Africa Health Regulator Flags First Death Linked to Johnson & Johnson COVID-19 Ja..
MT
08/04The Janssen Pharmaceutical Companies of Johnson & Johnson Announces European Commission..
CI
08/03DA Davidson Cuts Price Target on Johnson & Johnson to $190 From $196, Reiterates Buy/Ad..
MT
08/03Johnson & Johnson's Q2 Headwinds Pull Back Optimism on FY2022 Performance, D.A. Davidso..
MT
08/02Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conferen..
BU
08/01Johnson & Johnson's Janssen Pharmaceutical Secures FDA Approval for Psoriatic Arthritis..
MT
08/01JOHNSON & JOHNSON : STELARA® (ustekinumab) Approved by the U.S. Food and Drug Administrati..
PU
08/01J&J Gets FDA OK of Stelara for Pediatric Patients With Active Psoriatic Arthritis
DJ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 604 M - -
Net income 2022 21 415 M - -
Net cash 2022 10 065 M - -
P/E ratio 2022 20,9x
Yield 2022 2,56%
Capitalization 450 B 450 B -
EV / Sales 2022 4,60x
EV / Sales 2023 4,32x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 171,11 $
Average target price 185,55 $
Spread / Average Target 8,44%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-15.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.2.60%244 068
NOVO NORDISK A/S2.86%233 797